Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Actuate Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Actuate Therapeutics, Inc.’s stock price such as:

• Actuate Therapeutics, Inc.’s current stock price and volume
• Why Actuate Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for ACTU from analysts
• ACTU’s stock price momentum as measured by its relative strength

About Actuate Therapeutics, Inc. (ACTU)

Before we jump into Actuate Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company’s lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.

Want to learn more about Actuate Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Actuate Therapeutics, Inc..

Actuate Therapeutics, Inc.’s Stock Price as of Market Close

As of May 14, 2026, 9:45 AM, CST, Actuate Therapeutics, Inc.’s stock price was $2.880.

Actuate Therapeutics, Inc. is down 3.04% from its previous closing price of $2.970.

During the last market session, Actuate Therapeutics, Inc.’s stock traded between $2.828 and $2.940. Currently, there are approximately 23.53 million shares outstanding for Actuate Therapeutics, Inc..

Actuate Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Actuate Therapeutics, Inc. Stock Price History

Actuate Therapeutics, Inc.’s (ACTU) price is currently down 2.05% so far this month.

During the month of May, Actuate Therapeutics, Inc.’s stock price has reached a high of $3.430 and a low of $2.740.

Over the last year, Actuate Therapeutics, Inc. has hit prices as high as $11.990 and as low as $1.580. Year to date, Actuate Therapeutics, Inc.’s stock is down 52.94%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Actuate Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 13, 2026, there was 1 analyst who downgraded Actuate Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Actuate Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Actuate Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Actuate Therapeutics, Inc. (ACTU) by visiting AAII Stock Evaluator.

Relative Price Strength of Actuate Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 13, 2026, Actuate Therapeutics, Inc. has a weighted four-quarter relative price strength of -30.70%, which translates to a Momentum Score of 5 and is considered to be Very Weak.

Want to learn more about how Actuate Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Actuate Therapeutics, Inc. Stock Price: Bottom Line

As of May 14, 2026, Actuate Therapeutics, Inc.’s stock price is $2.880, which is down 3.04% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Actuate Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.